On October 29, 2018 Lonza Group Ltd. announced the acquisition of a controlling stake in Octane Biotech, with the right to acquire full ownership. The increase in equity share will allow Lonza to further develop the technology to support the growing need for scalable autologous manufacturing. Octane Orthobiologics Inc. will maintain exclusivity to a certain subset of orthopedic clinical indications for use in the CocoonTM system. Lonza is one of the world’s leading suppliers to the pharmaceutical, biotech and specialty ingredients markets. Fasken advised Lonza in this transaction with a team comprised of Aaron Atkinson (Corporate/M&A), Nicole Park (Corporate/M&A), Laurie Turner (Corporate/M&A), Chris Steeves (Tax)
Client Work
Lonza Acquires controlling stake acquisition in Octane Biotech to further develop Cocoon autologous technology
Fasken
Reading Time
1 minute read
Overview
Overview
Team
Team
- Nicole Park, Partner, Toronto, ON, +1 416 943 8902, npark@fasken.com
- Laurie M. Turner, Partner | CO-LEADER, HEALTH LAW GROUP, Toronto, ON, +1 416 868 3446, lturner@fasken.com
- Christopher Steeves, Partner | Leader, Tax Law, Toronto, ON, +1 416 868 3401, csteeves@fasken.com
